DNEX Dionex Corp. (MM)

For the third quarter of fiscal 2011, sales were $123.1 million, an increase of 9% compared with the $112.8 million reported in the same quarter of last year. Currency fluctuations increased sales by 2 percentage points for the third quarter compared with the same period last year. Diluted earnings per share for the quarter were $0.94, a decrease of 5% compared with $0.99 reported in the same quarter of last year.

For the first nine months of fiscal 2011, sales were $350.1 million, an increase of 12% compared with the $312.6 million reported for the first nine months of fiscal 2010. Currency fluctuations did not have a significant impact on net sales for the first nine months of fiscal 2011. Diluted earnings per share for the first nine months of fiscal 2011 were $2.60, an increase of 5% compared with the $2.48 reported in the first nine months of fiscal 2010.

Frank Witney, President and Chief Executive Officer, commenting on the results, said, "We are pleased to have maintained our revenue growth momentum in the third quarter as we continue to work towards our merger with Thermo Fisher Scientific, Inc. Sales in each of our major geographic regions grew in the quarter. Net sales in North America increased by 12% for the quarter compared to the same period last year. European sales were up by 9% in reported dollars. Favorable currency fluctuations affected our reported sales growth in Europe by 2%. Growth in both of these regions was driven by our HPLC portfolio, specifically the strong commercial acceptance of our new UHPLC+ systems introduced in the fourth quarter of our fiscal 2010. Our Asia/Pacific sales were up by 8% in reported dollars. Favorable currency fluctuations affected our reported sales growth by 4%. The overall growth in Asia/Pacific was primarily due to continued strong demand for all of our HPLC products in China, India and Korea partially offset by a large order in Japan in the same quarter of last year. Operating income and diluted earnings per share for the quarter were affected by lower gross profit resulting from significantly higher HPLC sales, costs associated with moving the manufacturing of our ESA products, the effect of a large ion chromatography order in Japan in the third quarter of last year coupled with slightly higher operating expenses."

As previously reported on December 13, 2010, the Company has entered into an Agreement and Plan of Merger with Thermo Fisher Scientific Inc. As previously disclosed, the HSR waiting period in the US expired in early January. Thermo Fisher is in the process of seeking similar clearances under anti-trust laws of other jurisdictions, and we expect to complete the acquisition in our fiscal fourth quarter.

Dionex Corporation is a leading manufacturer and marketer of chromatography systems for chemical analysis. The Company's systems are used in environmental analysis and by the life sciences, food and beverage, chemicals, petrochemicals, power generation and electronics industries in a variety of applications.

Certain statements contained herein are not purely historical are forward-looking statements. Factors that may cause actual results to differ from these statements are foreign currency fluctuations, ability to attract and retain qualified personnel, economic conditions in the areas in which the company sells its products and demand for analytical instrumentation. These factors and other risks and uncertainties are discussed in greater detail in the Company's most recent reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission.

CONTACT: Craig McCollam
         Dionex Corporation
         408-481-4107

Dionex Corp. (MM) (NASDAQ:DNEX)
Historical Stock Chart
From Oct 2024 to Nov 2024

Dionex Corp. (MM) (NASDAQ:DNEX)
Historical Stock Chart
From Nov 2023 to Nov 2024